Promoter Jagdishkumar Devjibhai Ajudiya disclosed holding a 68.29% stake in Indo Us Bio-Tech as on March 31, 2026, confirming no encumbrance of shares during the financial year. The disclosure was submitted to the National Stock Exchange of India in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shareholding Details

The filing details the promoter's shareholding position at the end of FY26. Ajudiya declared holding 1,36,93,643 shares, which constitutes 68.29% of the total paid-up capital of the company. The disclosure explicitly states that no shares were encumbered, directly or indirectly, throughout the financial year ended March 31, 2026.

Regulatory Compliance

The disclosure was made pursuant to Regulation 31(4) of the SEBI (SAST) Regulations, 2011. This regulation requires promoters to submit an annual declaration of their shareholding at the end of each financial year. The letter, dated April 10, 2026, was submitted on behalf of all promoters of Indo Us Bio-Tech Limited.

Indo Us Bio-Tech Limited has restructured its audit oversight by appointing M/s. Bhagat & Associates as its statutory auditor, effective June 16, 2026. The Board of Directors approved this appointment during its meeting held on June 16, 2026, following the resignation of the previous auditor. The appointment is subject to shareholder approval and remains valid until the conclusion of the next General Meeting.

M/s. Gautam N Associates, Chartered Accountants (FRN: 103117W), tendered their resignation as statutory auditor effective June 15, 2026. The firm cited administrative and operational restructuring of the company's audit assignments as the reason for cessation. The resignation letter confirmed there were no material reasons other than those stated and noted the company's intent to optimize logistical efficiencies by appointing an auditor based closer to its registered office in Ahmedabad.

M/s. Bhagat & Associates, Chartered Accountants (FRN: 101100W), has been appointed to fill the vacancy. The firm confirmed its eligibility and consent for the role, stating there are no proceedings pending against it or its partners regarding professional conduct. The firm also confirmed it has no relationship with the company's directors or key managerial personnel. The appointment aligns with Section 139 of the Companies Act, 2013 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Auditor Changes

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD1/114/2019 dated October 18, 2019. Ms. Dimpy Joshi, Company Secretary & Compliance Officer, signed the regulatory filing.